Patents by Inventor Josef Stadlwieser
Josef Stadlwieser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9376442Abstract: The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase and are useful for treating or preventing idiopathic pulmonary lung fibrosis.Type: GrantFiled: November 19, 2014Date of Patent: June 28, 2016Assignee: Takeda GmbHInventors: Josef Stadlwieser, Beate Schmidt, Heiko Bernsmann, Torsten Dunkern, Ewald Benediktus, Andreas Pahl, Ragna Hussong, Olaf Nimz, Matthias Mueller, Martin Viertelhaus
-
Publication number: 20160108049Abstract: The compounds of formula (1), in which R1, R7, R8, R9, R10, R17, R18, R19, R20 and m have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.Type: ApplicationFiled: December 3, 2015Publication date: April 21, 2016Inventors: Thomas STENGEL, Thomas MAIER, Alexander MANN, Josef STADLWIESER, Dieter FLOCKERZI, Andreas PAHL, Ewald BENEDIKTUS, Manuela HESSMANN, Tobias KANACHER, Ragna HUSSONG, Christof ZITT, Hans Christof HOLST, Rolf-Peter HUMMEL, Martin VIERTELHAUS, Hermann TENOR, Torsten DUNKERN, Armin HATZELMANN, Christian HESSLINGER
-
Publication number: 20150073001Abstract: The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase and are useful for treating or preventing idiopathic pulmonary lung fibrosis.Type: ApplicationFiled: November 19, 2014Publication date: March 12, 2015Inventors: Josef STADLWIESER, Beate SCHMIDT, Heiko BERNSMANN, Torsten DUNKERN, Ewald BENEDIKTUS, Andreas PAHL, Ragna HUSSONG, Olaf NIMZ, Matthias MUELLER, Martin VIERTELHAUS
-
Patent number: 8927557Abstract: The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.Type: GrantFiled: August 24, 2010Date of Patent: January 6, 2015Assignee: Takeda GmbHInventors: Josef Stadlwieser, Beate Schmidt, Heiko Bernsmann, Torsten Dunkern, Ewald Benediktus, Andreas Pahl, Ragna Hussong, Olaf Nimz, Matthias Mueller, Martin Viertelhaus
-
Patent number: 8816085Abstract: The compounds of Formula (I), wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.Type: GrantFiled: August 24, 2010Date of Patent: August 26, 2014Assignee: Takeda GmbHInventors: Josef Stadlwieser, Beate Schmidt, Heiko Bernsmann, Alexander Sudau, Torsten Dunkern, Ragna Hussong, Ewald Benediktus, Andreas Pahl
-
Publication number: 20140112945Abstract: The compounds of formula (1) in which R1, R7, R8, R9, R10, R17, R18, R19, R20 and m have the meanings as given in the description, are novel effective inhibitors of type 4 and type 5 phosphodiesterase.Type: ApplicationFiled: June 12, 2012Publication date: April 24, 2014Applicant: TAKEDA GmbHInventors: Thomas Stengel, Thomas Maier, Alexander Mann, Josef Stadlwieser, Dieter Flockerzi, Andreas Pahl, Ewald Benediktus, Manuela Hessmann, Tobias Kanacher, Ragna Hussong, Christof Zitt, Hans Christof Holst, Rolf-Peter Hummel, Martin Viertelhaus, Hermann Tenor, Torsten Dunkern, Armin Hatzelmann, Christian Hesslinger
-
Patent number: 8445501Abstract: The compounds of Formula (I), in which R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase.Type: GrantFiled: February 25, 2009Date of Patent: May 21, 2013Assignee: Takeda GmbHInventors: Josef Stadlwieser, Beate Schmidt, Heiko Bernsmann, Alexander Sudau, Torsten Dunkern, Degenhard Marx, Jörg Diefenbach
-
Publication number: 20120149721Abstract: The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.Type: ApplicationFiled: August 24, 2010Publication date: June 14, 2012Applicant: NYCOMED GMBHInventors: Josef Stadlwieser, Beate Schmidt, Heiko Bernsmann, Torsten Dunkern, Ewald Benediktus, Andreas Pahl, Ragna Hussong, Olaf Nimz, Matthias Mueller, Martin Viertelhaus
-
Publication number: 20120142633Abstract: The compounds of Formula (I), wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.Type: ApplicationFiled: August 24, 2010Publication date: June 7, 2012Applicant: NYCOMED GMBHInventors: Josef Stadlwieser, Beate Schmidt, Heiko Bernsmann, Alexander Sudau, Torsten Dunkern, Ragna Hussong, Ewald Benediktus, Andreas Pahl
-
Patent number: 7879853Abstract: The invention relates to novel pyrimidine derivatives of Formula (1) which are efficacious inhibitors of protein kinases, in particular of one or more isoforms of the protein kinase B/Akt.Type: GrantFiled: June 28, 2005Date of Patent: February 1, 2011Assignee: Bayer Schering Pharma AGInventors: Josef Stadlwieser, Thomas Baer, Thomas Maier, Thomas Beckers, Thomas Ciossek, Armin Zuelch, Ulrich Graedler
-
Publication number: 20110021479Abstract: The compounds of Formula (I), in which R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase.Type: ApplicationFiled: February 25, 2009Publication date: January 27, 2011Applicant: NYCOMED GMBHInventors: Josef Stadlwieser, Beate Schmidt, Heiko Bernsmann, Alexander Sudau, Torsten Dunkern, Degenhard Marx, Jörg Diefenbach
-
Publication number: 20080242681Abstract: Compounds of a certain formula 1 in which R1 and R2 have the meanings indicated in the description are novel kinase inhibitors. Formula (1), in which R1 is phenyl, phenyl substituted by R3 and/or R4, naphthalenyl, naphthalenyl substituted by and/or R6, aryl1, aryl1 substituted by R7 and/or R8, R9, R10 or R11, R2 is phenyl, phenyl substituted by R12 and/or R13, naphthalenyl, naphthalenyl substituted by R14 and/or R15, aryl2, aryl2 substituted by R16 and/or R17 or a radical selected from Formula (2).Type: ApplicationFiled: January 19, 2005Publication date: October 2, 2008Applicant: Altana Pharma AGInventors: Johannes Barsig, Monika Baudler, Daniela Bundschuh, Florian Gantner, Ulrich Graedler, Isabelle Heit, Thomas Martin, Michaela Schaefer, Imre Schlemminger, Josef Stadlwieser, Wolf-Ruediger Ulrich
-
Publication number: 20070208034Abstract: The invention relates to novel pyrimidine derivatives of Formula (1) which are efficacious inhibitors of protein kinases, in particular of one or more isoforms of the protein kinase B/Akt.Type: ApplicationFiled: June 28, 2005Publication date: September 6, 2007Applicant: Atlanta Pharma AGInventor: Josef Stadlwieser
-
Publication number: 20050222186Abstract: The invention relates to substituted diaminopyrimidine compounds, which are effective therapeutic compounds for treating diseases and disorders associated with those commonly treated by Protein Kinase C theta (PKC?) inhibitors.Type: ApplicationFiled: June 7, 2003Publication date: October 6, 2005Applicant: Altana Pharma AGInventors: Monika Baudler, Shripad Bhagwat, Paul Erdman, Florian Gantner, Moorthy Palanki, Christian Schudt, Josef Stadlwieser, James Zapf
-
Patent number: 6818651Abstract: 3,4-Dihydroisoquinoline and isoquinoline compounds of formula I, in which Ar represents a phenyl raidcal of the formulae IIa, IIb or IIc are novel effective PDE7 inhibitors.Type: GrantFiled: August 21, 2003Date of Patent: November 16, 2004Assignee: Altana Pharma AGInventors: Steffen Weinbrenner, Beate Schmidt, Gerhard Grundler, Josef Stadlwieser, Armin Hatzelmann, Geert Jan Sterk
-
Patent number: 6613769Abstract: The invention relates to bifunctional tryptase inhibitors of formula (I) wherein H1 and H2 comprise a Q group and L is a linker of formula and the conformation of the H1, H2 and L groups is such that the groups are separated by a distance of from 20 to 45 Å. Pharmaceutical compositions and crystal forms of the compounds are described in addition to methods for producing and identifying such compounds, as well as the use of such compounds in methods of treating allergic and inflammatory diseases.Type: GrantFiled: January 22, 2001Date of Patent: September 2, 2003Assignees: Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V., Altana Pharma AGInventors: Wolfram Bode, Luis Moroder, Pedro Jose Barbosa Pereira, Andreas Bergner, Robert Huber, Christian Sommerhoff, Norbert Schaschke, Thomas Bär, Thomas Martin, Josef Stadlwieser, Wolf-Rüdiger Ulrich, Andreas Dominik, Ulrich Thibaut, Daniela Bundschuh, Rolf Beume, Karl-Josef Goebel
-
Patent number: 6489327Abstract: The invention relates to novel inhibitors of human tryptase which are used in the pharmaceutical industry for the production of medicaments.Type: GrantFiled: October 20, 2000Date of Patent: December 3, 2002Assignees: Max-Planck-Gesellschaft zur Fordrungder Wisenschaften, e.V., Byk Gulden Lomberg Chemische Fabrik GmbHInventors: Thomas Bär, Thomas Martin, Josef Stadlwieser, Wolf-Rüdiger Ulrich, Andreas Dominik, Ulrich Thibaut, Daniela Bundschuh, Rolf Beume, Karl-Josef Goebel, Wolfram Bode, Luis Moroder, Pedro Jose Barbosa Pereira, Andreas Bergner, Robert Huber, Christian Sommerhoff, Norbert Schaschke
-
Patent number: 6136969Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is phenyl or alpha- or beta-naphthyl, which groups can be substituted by hydroxy, lower-alkyl, lower-alkoxy, lower alkoxy-carbonyl, phenoxy, acyloxy, hydroxyphenoxy-sulfonyl, halogen, nitro, amino, acylamino or N-lower-alkyl-acylamino;R.sup.2 is phenyl or phenyl substituted by hydroxy or acyloxy;Y is a carbon-carbon bond or is vinylene; andn is 1,2 or 3;and pharmaceutically acceptable acid addition salts thereof are protein kinase inhibitors and can be used for the treatment of disorders mediated by such enzymes, for example, inflammatory diseases.Type: GrantFiled: December 17, 1998Date of Patent: October 24, 2000Assignee: Hoffmann-La Roche Inc.Inventors: Pierre Barbier, Josef Stadlwieser, Sven Taylor
-
Patent number: 5914406Abstract: The compounds of formula I: wherein R.sup.1 --R.sup.9, R.sup.15, A, X, Y, and Z have the meaning given in the specification are active as protein kinase inhibitors and can be used as medicaments, particularly for the treatment of inflammatory skin disorders and alopecia.Type: GrantFiled: February 6, 1998Date of Patent: June 22, 1999Assignee: Hoffman-LA Roche Inc.Inventors: Pierre Barbier, Isabelle Huber, Fernand Schneider, Josef Stadlwieser, Sven Taylor
-
Patent number: 5907038Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is phenyl or alpha- or beta-naphthyl, which groups can be substituted by hydroxy, lower-alkyl, lower-alkoxy, lower alkoxycarbonyl, phenoxy, acyloxy, hydroxyphenoxy-sulfonyl, halogen, nitro, amino, acylamino or N-lower-alkyl-acylamino;R.sup.2 is phenyl or phenyl substituted by hydroxy or acyloxy;Y is a carbon-carbon bond or is vinylene; andn is 1,2 or 3;and pharmaceutically acceptable acid addition salts thereof are protein kinase inhibitors and can be used for the treatment of disorders mediated by such enzymes, for example, inflammatory diseases.Type: GrantFiled: March 31, 1997Date of Patent: May 25, 1999Assignee: Hoffmann-La Roche Inc.Inventors: Pierre Barbier, Josef Stadlwieser, Sven Taylor